AssetMark’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
AssetMark's XPH Position: Q3 2026 in Review
AssetMark held its State Street SPDR S&P Pharmaceuticals ETF (XPH) position steady in Q3 2026 at 125 shares worth $8.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2590.
AssetMark first reported a position in XPH in Q4 2016 and has held it in 3 quarters since. The position peaked at $8.28K in Q2 2026. 99 funds tracked by Wall St. Rank hold XPH as of Q3 2026.
- AssetMark held 125 shares of State Street SPDR S&P Pharmaceuticals ETF worth $8.12K as of Q3 2026.
- AssetMark left its State Street SPDR S&P Pharmaceuticals ETF share count unchanged in Q3 2026.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2590 holding.
- AssetMark first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2016 and has held it in 3 quarters since.
- AssetMark's State Street SPDR S&P Pharmaceuticals ETF position peaked at $8.28K in Q2 2026.
- 99 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.